The Department of the Army, through the US Army Medical Research and Development Command (USAMRAA), is offering the Fiscal Year 2024 Psychedelic Treatment Research Clinical Trial Award (PTRCTA) to support clinical trials evaluating treatments for post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI) using covered psychedelic substances. Applicants must focus on at least one of the specified conditions and select from a list of approved psychedelics, with the goal of conducting trials that assess safety and efficacy outcomes among active-duty Service Members. This initiative, with an estimated total funding of $9.8 million, aims to foster collaborations across military, academic, and federal institutions, ensuring that the proposed studies benefit Service Members while addressing women's health considerations. Interested parties should submit their applications by October 4, 2024, and can reach the CDMRP Help Desk at help@eBRAP.org for further inquiries.